Payment overview · 2025
General Payments
$245.93
9 reported records · 6 companies
Healthcare provider profile · identity verified
William John Mark Roach, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · VISALIA, CA · NPI 1538125497
Verified facts
What the public records show
CMS Open Payments records show William John Mark Roach, M.D. received $245.93 in general payments during 2025 across 9 reported records.
Haemonetics Corporation accounted for 32.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Haemonetics Corporation | Unresolved — no canonical attribution shown | $79.51 | 32.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $74.27 | 30.2% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $32.89 | 13.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $21.29 | 8.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.57 | 8.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.40 | 7.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $245.93 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TEG6S HEMOSTASIS SYSTEM Normalized: teg6s hemostasis system |
Device | Haemonetics Corporation | $79.51 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $50.11 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $43.73 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $32.89 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $21.29 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 116 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
116 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
116 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
83 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 301 | 100 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 185 | 33 |
| Metformin Hcl | Metformin Hcl | 185 | 59 |
| Amlodipine Besylate | Amlodipine Besylate | 164 | 50 |
| Gabapentin | Gabapentin | 162 | 53 |
| Lisinopril | Lisinopril | 159 | 54 |
| Levothyroxine Sodium | Levothyroxine Sodium | 152 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 143 | 39 |
| Omeprazole | Omeprazole | 140 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 132 | 53 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 132 | 39 |
| Irbesartan | Irbesartan | 116 | 32 |
| Jardiance | Empagliflozin | 116 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 114 | 31 |
| Sertraline Hcl | Sertraline Hcl | 112 | 33 |
| Alendronate Sodium | Alendronate Sodium | 111 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 104 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 98 | 27 |
| Mirtazapine | Mirtazapine | 93 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 87 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 87 | 31 |
| Tramadol Hcl | Tramadol Hcl | 87 | 22 |
| Losartan Potassium | Losartan Potassium | 83 | 27 |
| Ozempic | Semaglutide | 83 | 18 |
| Furosemide | Furosemide | 78 | 28 |
| Nortriptyline Hcl | Nortriptyline Hcl | 78 | 11 |
| Eliquis | Apixaban | 71 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 70 | 20 |
| Montelukast Sodium | Montelukast Sodium | 67 | 20 |
| Trazodone Hcl | Trazodone Hcl | 63 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 60 | suppressed |
| Potassium Chloride | Potassium Chloride | 60 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 59 | 19 |
| Buspirone Hcl | Buspirone Hcl | 57 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 54 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 53 | 15 |
| Allopurinol | Allopurinol | 51 | 19 |
| Famotidine | Famotidine | 49 | 13 |
| Simvastatin | Simvastatin | 49 | 12 |
| Carvedilol | Carvedilol | 48 | 18 |
| Baclofen | Baclofen | 47 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 44 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 44 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 44 | 12 |
| Pregabalin | Pregabalin | 44 | suppressed |
| Ezetimibe | Ezetimibe | 42 | 11 |
| Glimepiride | Glimepiride | 41 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 40 | suppressed |
| Spironolactone | Spironolactone | 40 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 37 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | 13 |
| Lorazepam | Lorazepam | 36 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 36 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | 11 |
| Meloxicam | Meloxicam | 30 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | 13 |
| Memantine Hcl | Memantine Hcl | 28 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 28 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Valsartan | Valsartan | 26 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Cephalexin | Cephalexin | 24 | 12 |
| Lactulose | Lactulose | 23 | suppressed |
| Alprazolam | Alprazolam | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 22 | suppressed |
| Movantik | Naloxegol Oxalate | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 12 |
| Ibuprofen | Ibuprofen | 21 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 21 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 12 |
| Lovastatin | Lovastatin | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 17 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 16 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 11 |
| Clonazepam | Clonazepam | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Lacosamide | Lacosamide | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Modafinil | Modafinil | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 13 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Tilia Fe | Norethindrone-E.Estradiol-Iron | 13 | suppressed |
| Armour Thyroid | Thyroid,pork | 12 | suppressed |
| Azithromycin | Azithromycin | 12 | 12 |
| Byetta | Exenatide | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 11 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $245.93 · 9 records | Haemonetics Corporation | Dexcom G6 Transmitter, JARDIANCE, MOUNJARO, TEG6S HEMOSTASIS SYSTEM, VRAYLAR, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error